ICAD_OUT_1 [2025-04-15 16:10:06 -0400] 4384 Bytes | 1140 tokens | Cum: 1140 tkns (14.25% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Icad (ICAD) which is at 3.3700 up from 1.8200. So, I pulled together a bunch of data for you to look over real fast. It's still early, 4:10:05 PM on Tue Apr 15, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Icad (ICAD)
IPO: 1992-03-17 (33 Years Ago)
Market Cap: $49,805,541
Shares Outstanding: 27,370,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Here’s a list of headlines for Icad:

Today 04:01PM - RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer
Apr-08-25 10:19AM - iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
Mar-20-25 03:02AM - icad Inc (ICAD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic SaaS ...
Mar-19-25 07:01PM - ICAD targets SaaS growth with ProFound Cloud expansion and AI advancements
Mar-19-25 07:01PM 07:00PM - iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript
Mar-19-25 07:01PM 04:17PM - Icad: Q4 Earnings Snapshot
Mar-19-25 07:01PM 04:01PM - iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
Mar-11-25 08:00AM - iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-26T19:46:00Z - Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
B2 - 2025-02-19T13:00:00Z - iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
B3 - 2024-12-04T22:00:00Z - CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
B4 - 2024-11-06T13:00:00Z - iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
B5 - 2024-10-03T12:00:00Z - iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
B6 - 2024-07-26T10:41:00Z - Computer Aided Detection (CAD) - Global Strategic Business Report to 2030: Increasing Prevalence of Cancer Driving Growth, Increasing Demand for Automated Detection

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Icad (ICAD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ICAD_OUT_3 [2025-04-15 16:10:07 -0400] 967 Bytes | 254 tokens | Cum: 1396 tkns (17.45% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/26/3033279/0/en/Koios-Medical-and-iCAD-Partner-to-Expand-AI-Powered-Multi-Modality-Breast-Cancer-Detection-Solutions-at-ECR-2025.htmlKoios Medical and iCAD, Inc. announced a strategic partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. The collaboration integrates iCAD's ProFound AI Breast Health Suite for mammography with Koios SmartUltrasound, providing radiologists with an AI-powered pathway from screening to diagnosis.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_5 [2025-04-15 16:10:07 -0400] 967 Bytes | 276 tokens | Cum: 1674 tkns (20.93% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-11T14:18:00Z - US Computer Vision in Healthcare Market worth US$11.53 billion by 2029 with 24.0% CAGR | MarketsandM...
A2 - 2025-04-08T13:30:00Z - iCAD Appoints Mark Koeniguer as Chief Commercial Officer...
A3 - 2025-04-08T16:56:40Z - FEATURE ǀ Palau deports Chinese criminals, reinforces Indo-Pacific security...
A4 - 2025-04-08T15:14:57Z - iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer | T...
A5 - 2025-04-08T14:25:18Z - iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ICAD_OUT_7 [2025-04-15 16:10:08 -0400] 1181 Bytes | 332 tokens | Cum: 2008 tkns (25.10% of 8k)
==========================================================================

Showing A1 (chunk 1 of 9): A1:
**US Computer Vision in Healthcare Market worth US$11.53 billion by 2029 with 24.0% CAGR | MarketsandMarkets**Date: 2025-04-11Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-04/65098381-us-computer-vision-in-healthcare-market-worth-us-dollar-11-53-billion-by-2029-with-24-0-cagr-marketsandmarkets-008.htmDELRAY BEACH, Fla., April 11, 2025 /PRNewswire/ -- The US Computer Vision in Healthcare Market is projected to reach US$11.53 billion by 2029 from US$3.93 billion in 2024, at a high CAGR of 24.0% during the forecast period. The market is expanding due to the rapid growth of medical imaging data, which requires efficient analysis methods. Computer vision improves diagnostics by automating processes and enhancing accuracy. The rising demand for AI-driven solutions provides healthcare provid

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_9 [2025-04-15 16:10:09 -0400] 1181 Bytes | 252 tokens | Cum: 2262 tkns (28.27% of 8k)
==========================================================================

Showing A1 (chunk 2 of 9): ers with precise tools for diagnosis and treatment planning. In January 2025, the FDA published new draft guidance detailing guidelines for AI-enabled medical device submissions to encourage this expansion. The guidance seeks to expedite regulatory approvals and foster confidence in AI-driven healthcare solutions by addressing transparency, bias risk tactics, and whole product life cycle (TPLC) management. However, ensuring the accuracy and reliability of computer vision algorithms remains a challenge. As errors in complex medical imaging tasks can have serious consequences.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231790940

Browse in-depth TOC on "US Computer Vision in Healthcare Market"

294 - Tables

46 - Figures

356 - Pages

By Based on type, PC-based computer vision systems hold the largest share in the US computer vision in healthcare market

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_11 [2025-04-15 16:10:11 -0400] 1181 Bytes | 230 tokens | Cum: 2494 tkns (31.18% of 8k)
==========================================================================

Showing A1 (chunk 3 of 9): due to their powerful, affordable, and dependable solutions for diagnostic centers and hospitals. With their ability to handle complex image analysis and deep learning applications, they seamlessly integrate into existing medical workflows. Data security is a high priority in the US, and these systems offer greater control over sensitive patient data, which ensures HIPAA compliance. As most hospitals already have PC-based systems installed, the process is seamless and streamlined. Additionally, their ability to function offline guarantees continuous operation, eliminating the chances of interruption caused by connectivity problems. Combined, these benefits make PC-based computer vision systems the preferred option for medical imaging and diagnostics.

By Based on segment, the patient activity monitoring and fall prevention segment is growing rapidly in the US healthcare market, driven b

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_13 [2025-04-15 16:10:12 -0400] 1181 Bytes | 243 tokens | Cum: 2739 tkns (34.24% of 8k)
==========================================================================

Showing A1 (chunk 4 of 9): y an aging population and a stronger focus on elderly care. Computer vision provides constant, non-intrusive monitoring to detect fall risks early and enable quick intervention. Wearable devices and smart sensors improve safety, support patient independence, and reduce strain on caregivers and healthcare providers. Caregility Corporation (US) rolled out AI-based fall risk alerting in August 2024 in its iObserver solution, using edge-based computer vision to monitor patient motion and notify caregivers in real-time. By processing data locally on telehealth devices, the system avoids cloud dependency, ensuring cost efficiency, scalability, and better data privacy. This innovation reflects the growing adoption of AI-driven monitoring solutions, making fall prevention more effective and expanding remote care options in hospitals and home settings.

By Based on application, The growth of pred

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_15 [2025-04-15 16:10:13 -0400] 1181 Bytes | 214 tokens | Cum: 2955 tkns (36.94% of 8k)
==========================================================================

Showing A1 (chunk 5 of 9): ictive maintenance in the US computer vision healthcare market is driven by the increasing complexity of medical equipment, which needs continuous monitoring to prevent unexpected failures. Hospitals also must reduce expenses and optimize operations, which requires predictive maintenance to minimize downtime and maintenance expenses. The surge in IoT-equipped and networked medical devices increases predictive ability by allowing real-time data analysis and collection. Moreover, strict regulation and patient protection standards compel health facilities to deliver consistent equipment performance, further reinforcing the necessity of proactive maintenance. Advances in artificial intelligence and machine learning have enhanced failure detection quality, further accelerating predictive maintenance for greater use within healthcare facilities. All these drives the fast-paced growth of predic

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_17 [2025-04-15 16:10:16 -0400] 1181 Bytes | 320 tokens | Cum: 3277 tkns (40.96% of 8k)
==========================================================================

Showing A1 (chunk 6 of 9): tive maintenance solutions across the industry.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231790940

The key players functioning in the US computer vision in healthcare market include NVIDIA Corporation (US), Intel Corporation (US), Microsoft Corporation (US), Advanced Micro Devices, Inc. (US), Google, Inc. (US), Basler AG (Germany), AiCure (US), iCAD, Inc. (US), Thermo Fisher Scientific Inc. (US), SenseTime (China), KEYENCE CORPORATION (Japan), Assert AI (India), Artisight (US), LookDeep Inc. (US), care.ai (US), CareView Communications (US), VirtuSense (US), Teton (Denmark), viso.ai (Switzerland), NANO-X IMAGING LTD. (Israel), Comofi Medtech Pvt. Ltd. (India), Avidtechvision (India), Roboflow, Inc. (US), Optotune (US) and CureMetrix, Inc. (US).

For more information, Inquire Now!

Related Reports:

Healthcare Cloud Computing Market

Healthcare IT M

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_19 [2025-04-15 16:10:17 -0400] 1181 Bytes | 267 tokens | Cum: 3546 tkns (44.32% of 8k)
==========================================================================

Showing A1 (chunk 7 of 9): arket

Healthcare Analytics Market

Healthcare Payer Services Market

Healthcare Simulation Market

About MarketsandMarkets:

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_21 [2025-04-15 16:10:17 -0400] 1181 Bytes | 255 tokens | Cum: 3803 tkns (47.54% of 8k)
==========================================================================

Showing A1 (chunk 8 of 9): 25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, vis

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_23 [2025-04-15 16:10:18 -0400] 869 Bytes | 256 tokens | Cum: 4061 tkns (50.76% of 8k)
==========================================================================

Showing A1 (chunk 9 of 9): it www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/us-computer-vision-in-healthcare-market-worth-us11-53-billion-by-2029-with-24-0-cagr--marketsandmarkets-302426403.html

© 2025 PR Newswire

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_25 [2025-04-15 16:10:19 -0400] 1088 Bytes | 304 tokens | Cum: 4367 tkns (54.59% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7.

Management s Discussion and Analysis of Fin Cond and Results of Oper .

##TABLE_END

The following discussion and analysis of the Companys financial condition and results of operations should be read in conjunction with the Companys CONS finan...

S8 - 2024-11-13 10-Q iCAD, INC. & SUBSIDIARIES

Condensed Cons Balance Sheets

(In thousands, except for share and per share data)

(Unaudited)

September 30,

December 31,

2024

2023

Assets

Curr assets:

Cash and cash equiv

$ 18,793 $ 21,670 Trade accounts rece...

S9 - 2024-08-13 10-Q iCAD, INC. & SUBSIDIARIES

Condensed Cons Balance Sheets

(In thousands, except for share data)

(Unaudited)

June 30,

December 31,

2024

2023

Assets

Curr assets:

Cash and cash equiv

$ 20,353 $ 21,670 Trade accounts receivable, net of allo...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ICAD_OUT_27 [2025-04-15 16:10:22 -0400] 1181 Bytes | 258 tokens | Cum: 4627 tkns (57.84% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7.

Management s Discussion and Analysis of Financial Condition and Results of Operations .

##TABLE_END

The following discussion and analysis of the Companys financial condition and results of operations should be read in conjunction with the Companys consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K.

Results of Operations

Overview

iCAD, Inc. is a global leaderin AI-powered cancer detection whose mission is to create a world where cancer cant hide. Cancer can grow and spread the longer it survives hidden and undetected. Remaining undetected, cancer poses one of the greatest threats to life. With iCADs clinically validated, regulatory cleared industry-leading ProFound Breast Health Suite, cancer has no easy way to hide. The Companys ProFound Breast Health Suite enables medical providers and p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_29 [2025-04-15 16:10:24 -0400] 1181 Bytes | 255 tokens | Cum: 4884 tkns (61.05% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): rofessionals to accurately and reliably identify where cancer may be hiding because iCADs solutions are able to find it earlier, it is more easily eliminated. The ProFound Breast Health Suite offers solutions forbreastcancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications. Prior to the third quarter of 2023, the Company had two reporting segments: Detection and Therapy. The Company completed the sale of its Xoft (Therapy) business line on October 23, 2023. Accordingly, the Company has only one reporting segment, Detection. The results of Therapy operations for all periods presented are reflected as discontinued operations in the Consolidated Statements of Income. Unless otherwise indicated, all disclosures and amounts relate to the Companys continuing oper

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_31 [2025-04-15 16:10:24 -0400] 1181 Bytes | 252 tokens | Cum: 5138 tkns (64.22% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ations.

Powered by advances in artificial intelligence (AI), and built on one of the largest, most diverse US and global data sets, the ProFound Breast Health Suite uniquely offers solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammograms collection of images. The ProFound Detection solution scores cases and suspicious lesions, helping radiologists identify and focus on areas of most concern and highest suspicion of cancer. The ProFound Suites AI Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a womans breast anatomy from the mammogram image. The ProFound Risk solution provides a near-term probability for developing breast cancer in the next one or two years, making it more actionable and relevant than generalized lifetime risk scores. The ProFound Breast Arterial Calcificat

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_33 [2025-04-15 16:10:25 -0400] 1181 Bytes | 246 tokens | Cum: 5386 tkns (67.33% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ion solution in development and not commercially available, identifies the presence of breast arterial calcification which is proven to correlate with calcifications elsewhere in the body, raising awareness of cardiovascular or heart health concerns.

The ProFound Detection and Density AI solutions within the ProFound Breast Health Suite are cleared by the US Food Drug Administration (FDA), and have received CE mark and Health Canada licensing. Used by thousands of providers serving millions of patients, certain products within the ProFound Breast Health Suite are available in over 50 countries. iCAD estimates that ProFound has been used for more than 40 million mammograms worldwide in the last five years alone.

The Companys headquarters and warehouse facility are located in Nashua, New Hampshire. The Company has office space in Lyon, France.

Discussion of Operating Results:

Year End

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_35 [2025-04-15 16:10:25 -0400] 1181 Bytes | 342 tokens | Cum: 5730 tkns (71.62% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ed December 31, 2024 compared to Year Ended December 31, 2023

Revenue. Revenue for the year ended December 31, 2024 was $19.6 million compared with revenue of $17.3 million for the year ended December 31, 2023, an increase of $2.3 million, or 13.2%.

The table below presents the components of revenue for 2024 and 2023 (in thousands):

##TABLE_START For the year ended December 31,

2024

2023

$ Change

% Change

Detection revenue

Product and licenses

$ 12,532 $ 9,930 $ 2,602 26.2 % Services

7,076 7,388 (312 ) (4.2 )% Total

$ 19,608 $ 17,318 $ 2,290 13.2 % ##TABLE_END

Product and licenses revenue increased by $2.6 million and services revenue decreased by $0.3 million. The increase in product revenues is due primarily to higher subscription licenses.

Cost of revenue and gross profit for 2024 and 2023 were as follows (in thousands):

##TABLE_START For the year ended

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_37 [2025-04-15 16:10:26 -0400] 790 Bytes | 269 tokens | Cum: 6001 tkns (75.01% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): December 31,

2024

2023

Change

% Change

Product and licenses

$ 1,387 $ 1,387 $ 0.0 % Services

1,205 1,060 145 13.7 % Amortization and depreciation

381 86 295 343.0 % Total cost of revenue

2,973 2,533 440 17.4 % Gross profit

$ 16,635 $ 14,785 $ 1,850 12.5 % Gross profit %

84.8 % 85.4 % ##TABLE_END

Cost of Revenue . Total cost of revenue increased by $0.4 million, or 17.4%, from $2.5 million for the year ended December 31, 2023 to $2.9 million for the year ended December 3...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ICAD_OUT_39 [2025-04-15 16:10:34 -0400] 6590 Bytes | 1803 tokens | Cum: 7806 tkns (97.58% of 8k)
==========================================================================

This is our set of metrics for Icad.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+------------------------+
| Volume: 240,164 | Perf Month: -17.38% | Option/Short: Yes / Yes | Sales Y/Y TTM: -4.15% |
+---------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 473.47K | Perf Quarter: -1.28% | Short Float: 1.05% | ROE: -18.09% |
+---------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 0.51 | Index: - | Short Ratio: 0.57 | ROI: -19.49% |
+---------------------+----------------------+-------------------------+------------------------+
| RSI (14): 44.93 | Market Cap: 52.68M | Short Interest: 0.27M | Sales Surprise: 11.83% |
+---------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.18 | Shs Outstand: 26.35M | Beta: 1.48 | EPS Surprise: 42.64% |
+---------------------+----------------------+-------------------------+------------------------+
| SMA20: -3.11% | Shs Float: 25.78M | Sales Q/Q: 14.07% | P/E: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA50: -21.17% | Inst Own: 20.18% | Sales past 5Y: -6.49% | Earnings: Mar 19 AMC |
+---------------------+----------------------+-------------------------+------------------------+
| SMA200: 1.63% | Insider Own: 5.78% | Employees: 66 | |
+---------------------+----------------------+-------------------------+------------------------+
| Perf Week: 15.96% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+---------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading by Icad officers or majority shareholders (if available).

Inside Trans: ICAD INC (ICAD) by Lonnqvist Eric (See Remarks) on 2025-02-21
- Common Stock: 15833 shares at $0 (D)

Inside Trans: ICAD INC (ICAD) by Brown Dana R (See Remarks) on 2025-02-21
- Common Stock: 25833 shares at $0 (D)

Inside Trans: ICAD INC (ICAD) by Patel Rakesh (Unknown Title) on 2025-02-05
- Director Stock Option (right to buy): 8575 shares at $0 (D)

Inside Trans: ICAD INC (ICAD) by Doyle Michael John (Unknown Title) on 2025-02-05
- Director Stock Option (right to buy): 7482 shares at $0 (D)

Inside Trans: ICAD INC (ICAD) by Hricak Hedvig (Unknown Title) on 2025-02-05
- Director Stock Option (right to buy): 6641 shares at $0 (D)

Inside Trans: ICAD INC (ICAD) by Wood Susan Alyson (Unknown Title) on 2025-02-05
- Director Stock Option (right to buy): 10593 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 18940000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2707000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.93
Average Volume: 280285.91
30-Day High: 2.47
30-Day Low: 1.66

[Detailed Financials: Q3 2024]
- Total Assets: $37,107,000.0
- Total Liabilities: $7,734,000.0
- Total Equity: $29,373,000.0
- Current Assets: $26,106,000.0
- Current Liabilities: $6,496,000.0

[Income Statement: Q3 2024]
- Revenue: $4,217,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.07

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $38,939,000.0
- Total Liabilities: $7,979,000.0
- Total Equity: $30,960,000.0
- Current Assets: $27,815,000.0
- Current Liabilities: $6,559,000.0

[Income Statement: Q2 2024]
- Revenue: $5,029,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.07

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Icad (ICAD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Icad.

2) MARKET_SCORE[]
This conversation was initiated because ICAD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ICAD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ICAD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ICAD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Icad.

11) ETHICAL_RATING[]
Rate Icad’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Icad.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ICAD_IN_41 [2025-04-15 16:10:34 -0400] 126 Bytes | 29 tokens | Cum: 8052 tkns (100.65% of 8k)
==========================================================================

====================================
[2025-04-15 16:10:34] # Analysis Completed
Elapsed Time: 29.34 seconds